Home > Insider Trading > Filing (0001127602-17-031249)

Filing Details

Accession Number:: 0001127602-17-031249
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-11-03 17:53:44
Reporting Period:: 2017-11-01

Accepted Time:: 2017-11-03 17:53:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1472091	Edge Therapeutics Inc.	EDGE	Pharmaceutical Preparations (2834)	264231384

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1652973	A Brian Leuthner	300 Connell Drive, Suite 4000 Berkeley Heights NJ 07922	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2017-11-01	2,500	$10.92	102,736	No	4	S	Direct
Common Stock	Disposition	2017-11-02	2,500	$10.94	100,236	No	4	S	Direct
Common Stock	Disposition	2017-11-03	2,500	$10.86	97,736	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	162,000	Indirect	By Spouse
Common Stock	223,622	Indirect	By Trust

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.40 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.70 to $11.08 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.62 to $11.02 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.